Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ terbutaline hemisulfate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Bronchodilation: Terbutaline is a beta-2 adrenergic agonist that acts on beta-2 adrenergic receptors in the smooth muscles of the airways. By stimulating these receptors, terbutaline causes relaxation of bronchial smooth muscle, resulting in bronchodilation. This effect helps to relieve symptoms such as wheezing, shortness of breath, and chest tightness associated with asthma and COPD.

  2. Relief of Bronchospasm: Terbutaline is effective in relieving acute bronchospasm, which is characterized by sudden constriction of the airways. It provides rapid relief of symptoms during acute asthma attacks or exacerbations of COPD.

  3. Maintenance Therapy: In addition to providing quick relief of bronchospasm, terbutaline can also be used as a maintenance therapy to prevent or reduce the frequency of asthma symptoms. Regular use of terbutaline can help control asthma and improve lung function over time.

  4. Route of Administration: Terbutaline is available in various formulations, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulized solutions, and oral tablets. The choice of formulation depends on factors such as the patient's age, preference, and severity of the condition.

  5. Side Effects: Common side effects of terbutaline may include tremor, palpitations, headache, nervousness, dizziness, and muscle cramps. These side effects are usually mild and transient, but patients should notify their healthcare provider if they become bothersome or persistent.

  6. Cardiovascular Effects: Terbutaline can cause cardiovascular side effects such as tachycardia (rapid heartbeat), palpitations, and increases in blood pressure. Patients with pre-existing cardiovascular conditions should use terbutaline with caution and under the supervision of a healthcare provider.

  7. Hyperglycemia: Terbutaline may increase blood glucose levels, particularly in patients with diabetes. Close monitoring of blood glucose levels is recommended in diabetic patients receiving terbutaline therapy.

  8. Hypokalemia: Prolonged use of terbutaline may lead to hypokalemia (low potassium levels) due to its stimulatory effect on beta-2 adrenergic receptors in skeletal muscle and kidneys. Hypokalemia can cause muscle weakness, cardiac arrhythmias, and other adverse effects.

  9. Pregnancy and Lactation: Terbutaline should be used with caution during pregnancy, especially during the first trimester, as it may increase the risk of adverse pregnancy outcomes. It can be used during labor to relax the uterus (tocolysis) and prevent preterm labor. However, its use for this indication should be carefully monitored. Terbutaline can be excreted in breast milk, so breastfeeding women should consult their healthcare provider before using terbutaline.

  10. Drug Interactions: Terbutaline may interact with other medications, such as beta-blockers, monoamine oxidase inhibitors (MAOIs), and diuretics, potentially leading to additive cardiovascular effects or other adverse reactions. Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.


Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of terbutaline hemisulfate,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by terbutaline hemisulfate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.


Taxonomy Rank Effect Citations Notation
Lacticaseibacillus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of terbutaline hemisulfate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.2 0.2
Alzheimer's disease 0.6 -0.6
Ankylosing spondylitis 0.2 0.2
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0.2 0.2
Atrial fibrillation 0.4 0.4
Autism 0.2 0.6 -2
Barrett esophagus cancer 0.2 -0.2
Carcinoma 0.2 0.2
Celiac Disease 0.2 0.2
Cerebral Palsy 0.2 0.2
Chronic Fatigue Syndrome 0.7 0.2 2.5
Chronic Kidney Disease 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.6 0.6
Chronic Urticaria (Hives) 0.2 0.2
Coagulation / Micro clot triggering bacteria 0.2 0.2 0
Colorectal Cancer 0.4 0.2 1
Coronary artery disease 0.2 0.2
COVID-19 0.2 1.2 -5
Crohn's Disease 0.4 -0.4
deep vein thrombosis 0.2 -0.2
Depression 1.3 1.5 -0.15
Dermatomyositis 0.2 0.2
Eczema 0.6 -0.6
Endometriosis 0.2 0.2
Epilepsy 0.2 0.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 -0.2
Glioblastoma 0.2 -0.2
Halitosis 0.2 -0.2
Hidradenitis Suppurativa 0.2 0.2
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0.2 0
hypertension (High Blood Pressure 0.2 0.2 0
Inflammatory Bowel Disease 0.6 0.6 0
Insomnia 0.2 0.2
Liver Cirrhosis 0.2 0.2 0
Long COVID 0.4 0.2 1
ME/CFS with IBS 0.2 0.2
ME/CFS without IBS 0.3 0.3
Metabolic Syndrome 0.2 0.2 0
Mood Disorders 1.3 1.5 -0.15
multiple chemical sensitivity [MCS] 0.6 0.6
Multiple Sclerosis 0.6 0.6 0
Neuropathy (all types) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 0.4 -1
Obesity 0.2 1.1 -4.5
obsessive-compulsive disorder 0.2 0.2 0
Osteoarthritis 0.2 0.2
pancreatic cancer 0.2 0.2
Parkinson's Disease 0.2 0.4 -1
Psoriasis 0.2 0.2
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.2 0.2
Sjögren syndrome 0.2 0.2 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Systemic Lupus Erythematosus 0.2 0.2
Type 1 Diabetes 0.2 -0.2
Type 2 Diabetes 0.2 0.2 0
Ulcerative colitis 0.6 0.6
Unhealthy Ageing 0.2 0.4 -1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]